To ensure maximum safety, MarketsandMarkets has initiated a mandatory COVID-19 vaccination policy for all in-person attendees across all our physical events. Attendees will be asked to provide proof of vaccination. Additional details on the vaccine policy will be provided upon registration.

Attendees that cannot participate due to this policy, or because of any travel restrictions, are encouraged to participate in the event by registering virtually and attending the event which will be live streamed on our very well appreciated virtual event platform!

These policies may shift as the virus subsides, but we firmly feel this is the right time for MarketsandMarkets to reopen our much awaited physical events safely! We stay committed in our fight against COVID, a variety of new protocols and elevated practices are in place at the venue along with maintaining high standards of cleanliness. We are strictly adhering to the safety guidelines outlined by the Government. We also encourage our participants to review all federal, state, and local permitted traveler guidance before travel and making a reservation.

Revisiting a robust biosimilars market and following the next steps towards improving biosimilars access and uptake

The Biosimilars industry is experiencing significant growth due to the rising incidence of chronic diseases and the increasing demand for biosimilars due to their cost-effectiveness. The global biosimilars market size is expected to grow from USD 35.7 billion by 2025 from USD 11.8 billion in 2020, at a CAGR of 24.7%. However, with complexities in manufacturing and resistance from biologic manufacturers, such factors keeps adding to the hinderance in their development.

MarketsandMarkets 2nd Annual Biosimilars Conference will a hold discussions on key clinical attributes of biosimilars, perspective from different stakeholder regarding opportunities for the biosimilar market and how intense can the competition get.

The conference will also address perspective on global regulatory landscape and how partnerships can highly support R&D and production of biosimilars.

Witness discussions on importance of market access and marketing strategy and how should companies enhance their presence in the market.

2nd Annual MarketsandMarkets Biosimilars Conference

Revisiting a robust biosimilars market and following the next steps towards improving biosimilars access and uptake

Registration

Welcome note from MarketsandMarkets

Opening Remarks from the Chairman

Keynote presentation- Why Biosimilars are being used!

Current State of Biosimilars in the market

Solution Provider Presentation

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

Advancements in RnD and clinical pathways for developing biosimilars

Solution Provider Presentation

Deriving modified pathways for biosimilars drug manufacturing while adhering to the regulatory requirements

Solution Provider Presentation

Lunch and Poster Presentation | One-to-One Networking Meetings

Major factor in growth of Biosimilars - rising incidences for chronic diseases OR patent expiry of innovator biologic drug?

Emerging trends in biosimilar litigation

Overcoming the challenges of different payers using different biosimilars-How to set up Biosimilars in electronic medical record for easy transaction?

Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings

How are pharmacies dealing with the emerging challenges with the first round biosimilars (self-administered and self-injection drugs)

Panel Discussion- To be confirmed

Closing Remarks from the Chairman

Drinks Reception & Networking

End of Day 1

Registration

Welcome note from MarketsandMarkets

Opening Remarks from the Chairman

How to successfully commercialize biosimilars in Europe?

Collaboration is the key - Benefit of biosimilars research, registries and clinical trials partnerships

Solution Provider Presentation

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

Strategic repurposing of biosimilars - A sustainable solution to the effective management of the global COVID19 pandemic

Solution Provider Presentation

How should a company that only manufactures biosimilars build its marketing and market acces?s strategy to demonstrate value

Biosimilar commercialization & legal hurdles

Lunch and Poster Presentation | One-to-One Networking Meetings

COVID 19 impact on biosimilars - Reimbursement and market access issues post COVID

Future perspective on biosimilar drugs -Will this trend decline or will it continue?

Attractiveness and sustainability: Does European Biosimilar market comply with these requirements?

Closing Remarks from the Chairman

End of Conference

Scott Soefje

Scott Soefje

Michelle Bridenbaker

Michelle Bridenbaker

Michelle Bridenbaker

Michelle Bridenbaker

Eart J Cruz

Eart J Cruz

Bentham Science